v3.24.0.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities:    
Net loss $ (1,168,509) $ (5,542,142)
Adjustments to reconcile net loss to net cash used in operating activities:    
Acquired in-process research and development 12,000 100,000
Depreciation 3,211 3,211
Amortization of operating lease right-of-use asset 16,763 15,223
Share-based compensation 50,005 91,617
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 269,116 82,673
Incentive tax receivable 592,463 (619,118)
Other assets (77,656)
Accounts payable (465,735) (375,540)
Accrued expenses and other current liabilities (2,287,544) 383,362
Operating lease liability (17,225) (17,201)
Deferred income (18,626) (37,255)
Net cash used in operating activities (3,091,737) (5,915,170)
Cash flows from financing activities:    
Proceeds from sale of common stock, net of issuance costs 3,838,870 4,562,895
Net cash provided by financing activities 3,838,870 4,562,895
Net increase (decrease) in cash 747,133 (1,352,275)
Cash, beginning of period 2,274,259 3,052,879
Cash, end of period 3,021,392 1,700,604
Supplemental disclosure of non-cash operating, investing and financing activities:    
In-process research and development in accrued expenses 12,000 261,250
Offering costs in accounts payable and accrued expenses 15,000 138,878
Deferred offering costs charged against proceeds from sale of common stock $ 32,340

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL